Inhalation Innovation: Phase IIb Study Design of Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis - European Medical Journal

Continue

Inhalation Innovation: Phase IIb Study Design of Inhaled Pirfenidone in the Treatment of Progressive Pulmonary Fibrosis

1 Mins
Respiratory
Authors:
Martin Kolb,1 Colin Reisner,2 Deepthi Nair,3 Felix Woodhead,3 Howard Lazarus,3 *Craig Conoscenti3
  • 1. McMaster University, Hamilton, Canada
  • 2. DevPro Biopharma, Basking Ridge, New Jersey, USA
  • 3. Avalyn Pharma, Cambridge, Massachusetts, USA
*Correspondence to [email protected]
Disclosure:

Kolb has received payment from Avalyn Pharma for providing advice for the MIST trial; has received research funding for preclinical work from Boehringer Ingelheim, United Therapeutics, and Structure Therapeutics; has received consulting fees from Boehringer Ingelheim, Roche, Horizon, Abbvie, Bellerophon, Algernon, CSL Behring, United Therapeutics, Fortrea, Structure Therapeutics, Astra Zeneca, Sanofi, GSK, Pliant, Avalyn, and Trevi; has received payments or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Glenmark, Novartis, and Boehringer Ingelheim; and payment for expert testimony from Roche. Reisner is the CEO and co-founder of DevPro Biopharma and has provided consultation and consulting fees from Avalyn Pharma on the design and implementation of this study; has  grants and contracts with multiple pharma companies under confidentiality; has stock options in Astrazeneca, Immunocore, Albus Health, Novo, Sandoz and is an individual investor in multiple companies that DevPro Biopharma does not work with directly. Nair and Woodhead have received all the support for this manuscript from Avalyn Pharma as an employee; has stock options in Avalyn Pharma as an employee. Lazarus has received all the support for this manuscript from Avalyn Pharma as an employee. Conoscenti has received all the support for this manuscript from Avalyn Pharma as an employee; has stock options in Avalyn Pharma as an employee and receives salary from the same as an employee. Conoscenti all the support for this manuscript as the drug developer from Avalyn Pharma; has stock options at Avalyn Pharma and receives salary from the same as an employee. The authors declare no conflict of interest.

Citation:
EMJ Respir. ;12[1]:84-86. https://doi.org/10.33590/emjrespir/MXJY9650.
Keywords:
Antifibrotic, nintedanib, pirfenidone, progressive pulmonary fibrosis.

Each article is made available under the terms of the Creative Commons Attribution-Non Commercial 4.0 License.

INTRODUCTION 

Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of pulmonary fibrosis in patients with interstitial lung diseases (ILD) other than idiopathic pulmonary fibrosis (IPF).1 Oral pirfenidone has been studied in non-IPF ILDs but never achieved a statistically significant change in the primary endpoint. Trends seen in secondary endpoints support efficacy in PPF.2-4

OBJECTIVE

Data from the AP01-002 (ATLAS) Study of inhaled pirfenidone in IPF demonstrated efficacy and improved safety compared to that seen with oral pirfenidone.5 The AP01-007 (MIST Study, Figure 1) is designed to study the efficacy and safety of AP01 (aerosolised pirfenidone) in patients with PPF. Patients will remain on background immunosuppression, and up to 30% of patients will remain on background nintedanib therapy.

Figure 1: MIST study design.
BID: twice daily; TC: telephone call.

METHODS

The primary objective is to observe the change in the annual rate of decline in forced vital capacity in the AP01 treatment groups as compared to placebo. In addition, efficacy will be measured in secondary endpoints of time to progression, change in 6-minute walk test, change in fibrotic scores via quantitative high-resolution CT, and change from baseline quality of life. Safety outcomes will be assessed as well. Cough will be analysed through cough counts and cough questionnaires, which should allow differentiation of cough related to PPF versus the nebulisation procedure.

CONCLUSION

MIST will study the safety and efficacy of AP01 (aerosolised pirfenidone) in patients with PPF. In addition to the safety and efficacy endpoints, MIST will carefully examine the presence of cough in this population of patients.

References
Raghu et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: an official ATS/ERS/JRS/ALAT Clinical Practice Guideline. Am J Respir Crit Care Med. 2022;205(9)e18-47. Maher et al. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial. Lancet Respir Med. 2020;8(2):147-57. Behr et al. Pirfenidone in patients with progressive fibrotic interstitial lung diseases other than idiopathic pulmonary fibrosis (RELIEF): a double-blind, randomised, placebo-controlled, phase 2b trial. Lancet Respir Med. 2021;9(5):476-86. Fernandez-Perez et al. Pirfenidone in fibrotic hypersensitivity pneumonitis: a double-blind, randomised clinical trial of efficacy and safety. Thorax. 2023;78(11)1097-104. West A et al. Inhaled pirfenidone solution (AP01) for IPF: a randomised, open-label, dose-response trial. Thorax. 2023 Sep;78(9):882-9.

Rate this content's potential impact on patient outcomes

Average rating / 5. Vote count:

No votes so far! Be the first to rate this content.